• Patients
  • News
  • Bundaberg resident becomes first man in Australia to receive new combined prostate cancer treatment as part of large international clinical trial

Bundaberg resident becomes first man in Australia to receive new combined prostate cancer treatment as part of large international clinical trial

Recruitment now underway in Bundaberg

Bundaberg, Australia – GenesisCare and Wide Bay Hospital and Health Service (WBHHS) have today announced that a Bundaberg prostate cancer patient has become the first man in Australia to receive a new combined therapy, as part of a global clinical trial.

The global clinical trial, which is now open to eligible prostate cancer patients in the Wide Bay region, is examining the efficacy of combining radiation therapy with a drug called apalutamide and a luteinizing hormone-releasing agonist drug (LHRH).

Prostate cancer is the most common cause of cancer in Australian men, with about 16,700 men newly diagnosed each year. In the Wide Bay Burnett Region, approximately 266 men will be diagnosed with prostate cancer each year and 1 in 6 men will be diagnosed with prostate cancer by the time they are 80.

Dr Gerry Adams, GenesisCare Radiation Oncologist and Principal Investigator of the new study, said it was critically important for regional communities across Australia to have access to the latest clinical trials and new treatment options.

“The fact that the first ever participant on the clinical trial in Australia hails from right here in Bundaberg is a fantastic achievement and a credit to the entire team involved in getting the clinical trial up and running,” said Dr Adams.

“Sadly there are still significant disparities in health outcomes between regional and metropolitan cancer patients. It is well known that, when cancer centres are involved in clinical trials, the quality of treatment and outcomes improve – not just for individual patients, but the whole centre.

“Therefore, ensuring cancer patients can access to cutting-edge global clinical trials, closer to home, is one of the key ways in which we can close the gap in health outcomes and improve long-term survival rates for our patients,” said Dr Adams.

Wide Bay Hospital and Health Service Chief Executive, Debbie Carroll, said ensuring cancer patients can access world-class cancer care at their doorstep was at the cornerstone of its Care Comes First… Through Patients’ Eyes Strategic Plan 2018–2022.

“Wide Bay Hospital and Health Service is delighted to partner with GenesisCare on this ground-breaking clinical trial that may offer new hope to hundreds of men diagnosed with prostate cancer each year in the region.

“Our health service has placed a focus on returning a range of cancer treatments to the Wide Bay so people can access their care locally and our ongoing partnership with GenesisCare to provide a range of treatments that previously were not on offer locally is an important part of achieving this goal.

“It’s fantastic to now be partnering with GenesisCare on these clinical trials, providing new treatments to Wide Bay locals and in this case an Australian first.”

General Manager for GenesisCare in Queensland, Andrew Saunders, said: “Historically, local cancer patients would have to travel to Brisbane or even interstate to participate in new clinical trials and access the latest treatment options. Travelling for treatment can have a huge emotional, financial and physical burden on patients and their families.”

“Through our partnership with Wide Bay Hospital and Health Service, we have been able to bring the latest treatment techniques and technology to cancer patients in the region, as well as providing access to world-first clinical trials through our global network of doctors and centres,” continued Mr Saunders.

For more information on the clinical trial and eligibility requirements:

https://www.genesiscare.com/au/clinical-trial/primordium/